PeptiDream Inc is a privately-held biopharmaceutical company employing our proprietary Random Peptide Integrated Discovery (RAPID) Platform, a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics.  PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide.


Latest News & Publications

May 2009   

METI (Ministry of Economy, Trade, and Industry) names  PeptiDream Inc one of the top 20 University-startup companies in Japan.  ☞

May 2009   

European patent covering PeptiDream's 2nd generation Flexizyme technology granted.

Oct 2008   

PeptiDream Inc receives research grant from Japan Science and Technology Agency (JST), in collaboration with Doshisha University, for the development of peptide therapeutics for the treatment of Alzheimer's disease, targeting amyloid beta processing.

Aug 2008   

PeptiDream Inc receives research grant from the National Institute of Biomedical Innovation Science, in collaboration with The University of Tokyo, for the development of peptide therapeutics for the treatment of ALS, targeting mutant SOD1 and Derlin-1.

Jul 2007   

PeptiDream Inc enters into R&D collaboration with MedImmune, the biologics arm of Astra Zeneca.

Jul 2006   

PeptiDream Inc established.

Feb 2006   

US, European, and Japan patents covering PeptiDream's 1st generation Flexizyme technology granted.